A PHASE 2A RANDOMIZED, DOUBLE-BLIND, DOSE-OPTIMIZING STUDY TO EVALUATE THE IMMUNOGENICITY AND SAFETY OF A BIVALENT DNA VACCINE FOR HEMORRHAGIC FEVER WITH RENAL SYNDROME DELIVERED BY INTRAMUSCULAR ELECTROPORATION
Account has been disabled due to a violation of Terms of Service. Contact Moderators
Account has been disabled due to a violation of Terms of Service. Contact Moderators